TRIUMPH-9

RecruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

Enrollment

600

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07357415

Org study ID27795

Secondary IDJ1I-MC-GZQLEli Lilly and Company

Timeline

Milestones

Study first posted2026-01-22actual

Study start2026-01-24actual

Last update posted2026-05-22actual

Primary completion2028-10estimated (month precision)

Study completion2028-11estimated (month precision)

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have a Body Mass Index (BMI) at screening

–≥ 30 kilogram per square meter (kg/m2) OR

–≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease

•Have at least one unsuccessful attempt to lose weight by dieting

Exclusion criteria

•Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening

•Have a prior or planned surgical treatment for obesity

•Have type 1 diabetes or type 2 diabetes

•Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

•Have had within the past 90 days before screening:

–heart attack

–stroke

–hospitalization for unstable angina or heart failure

•Have New York Heart Association Functional Classification Class IV congestive heart failure

•Have a history of chronic or acute pancreatitis

•Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Patient-reported / QoL

Safety / tolerability / PK

Weight & body composition

2 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 104

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference

Time frame:Baseline, Week 104

Waist circumference, change

change from baseline, improvement

Cardiometabolic biomarkers

3 endpoints

Secondary/protocol endpoint

Percent Change from Baseline in Triglycerides

Time frame:Baseline, Week 104

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change from Baseline in Systolic Blood Pressure

Time frame:Baseline, Week 104

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Percent Change from Baseline in High Sensitivity C-Reactive Protein

Time frame:Baseline, Week 104

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score

Time frame:Baseline, Week 104

IWQOL-Lite total

change from baseline, improvement

Secondary/protocol endpoint

Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores

Time frame:Week 104

descriptive, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Pharmacokinetics (PK): Steady state Average Trough PK Concentration

Time frame:Baseline through Week 104

Plasma concentration (steady state)

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.